Speakers
Amr Abdeen
Postdoctoral Associate
University of Wisconsin- Madison
Discussion Day
3:00 pm | Improved Non-Viral Vectors for In Vivo Genome Editing
Omar Abudayyeh
McGovern Fellow
Harvard University
Day Two
Thursday May 21 2020
10:31 am | Harnessing Novel CRISPR Tools for Genome Engineering and RNA Editing
Fernando Aleman
Co-Founder & Chief Scientific Officer
Navega Therapeutics
Andrew Anzalone
Head of Prime Editing Platforms
Prime Medicine
Day One
Wednesday May 20 2020
10:00 am | Exploring the Potential of Prime Editing
Luis Barrera
Head of Computational Sciences
Beam Therapeutics
Day Two
Thursday May 21 2020
3:00 pm | Comprehensive Identification of Base Editor Off-Targets in the Context of Therapeutically Relevant Delivery
1:30 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?
Delai Chen
Associate Director, Nanoparticle Formulation
Beam Therapeutics
Discussion Day
1:15 pm | Panel Discussion: Discussing the Future of CRISPR Delivery: Will One Modality Emerge as Superior?
Paul Diehl
Chief Operating Officer
Cellecta
Day One
Wednesday May 20 2020
1:00 pm | Functional CRISPR Screening and Cell Barcoding to Identify Genes Driving Biological Responses and Disease Progression
Rafi Emmanuel
Research Director
Emendo Biotherapeutics
Day One
Wednesday May 20 2020
4:15 pm | Target Optimized Variant of CRISPR Associated Nuclease Enables Allele-Specific Knock Out of ELANE-Related Neutropenia
Jonathan Gootenberg
McGovern Fellow
Harvard University
Day Two
Thursday May 21 2020
10:30 am | CRISPR Diagnostics: Expanding the Nucleic Acid Detection Toolbox by Harnessing Microbial Diversity
Julian Grunewald
Research Fellow
Joung Lab, Massachusetts General
Day One
Wednesday May 20 2020
10:30 am | Developing and Improving Base Editors
Killian Hanlon
Research Fellow
Harvard University
Discussion Day
11:15 am | Overcoming Limitations of Viral Vectors to Deliver CRISPR Machinery
Ben Kleinstiver
Principal Investigator
Massachusetts General
Day Two
Thursday May 21 2020
1:00 pm | Broadly Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties
Sanne Klompe
Graduate
Sternberg Lab, Columbia University
Day One
Wednesday May 20 2020
12:30 pm | Utilizing CRISPR-Associated Transposons for Programmed Insertions Without Generating Double-Strand Breaks
Kunwoo Lee
Chief Executive Officer & Co-Founder
GenEdit
Discussion Day
1:15 pm | Panel Discussion: Discussing the Future of CRISPR Delivery: Will One Modality Emerge as Superior?
12:45 pm | Non-Viral Delivery of CRISPR Using Polymer Nanoparticles
Blair Madison
Senior Director, Genetic Engineering
Poseida Therapeutics
Day Two
Thursday May 21 2020
3:30 pm | Creating Novel Proteins to Optimize Efficacy and Specificity
1:30 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?
Peter Marks
Director, CBER
FDA
Day Two
Thursday May 21 2020
9:30 am | FDA’s Regulatory Approach to Applications of CRISPR
Niren Murthy
Professor
University of California at Berkeley
Discussion Day
12:15 pm | Gene Editing After Local Injection: Non-Viral Delivery
Kiran Musunuru
Principal Investigator
University of Pennsylvania
Day Two
Thursday May 21 2020
2:30 pm | Applying CRISPR to Predict and Treat Cardiovascular Disease
Kalina Paunovska
Postdoctoral Fellow
Dahlman Lab, Georgia Tech
Discussion Day
3:30 pm | Delivering CRISPR Apparatus In Vivo Using Nanoparticle Technology
Karl Petri
Research Fellow
Joung Lab, Massachusetts General
Day One
Wednesday May 20 2020
5:15 pm | ONE-seq: Detection of CRISPR Nuclease and Base Editor Off-Targets with Ultra-High Sensitivity to Ensure the Safety of CRISPR Therapeutics
Sicco Popma
Founder, Chief Executive Officer & President
IO Biosciences
Day Two
Thursday May 21 2020
5:00 pm | Developing CRISPR-Based Cell Therapies Using a Proprietary Gene Editing System (GEMS)
Satinder Rawat
Senior Licensing Officer
University of Massachusetts
Day One
Wednesday May 20 2020
3:45 pm | Bridging the Gap Between Academia and Industry: Translating Cutting-Edge Technologies from the Lab to the Clinic
David Schaffer
Co-Founder
4D Molecular Therapeutics
Discussion Day
10:45 am | Directed Evolution of Novel AAV Variants for Clinical Gene Therapy
Brett Staahl
Founder & Head of Applied Technologies
Scribe Therapeutics
Discussion Day
10:15 am | Why Isn’t the Future of Medicine Here Yet?
Marija Tadin- Strapps
Vice President, Exploratory Biology
SQZ Biotechnologies
Discussion Day
4:00 pm | CellSQZ platform for Development of Next Generation Cell Therapies
Fyodor Urnov
Scientific Director
Innovative Genomics Institute
Day One
Wednesday May 20 2020
6:15 pm | Chair’s Closing Remarks
9:30 am | KEYNOTE: CRISPR 2030: the Promise and the Challenge
9:20 am | Chair’s Opening Remarks
Rui Wang
Principal Research Scientist
Abbvie
Renee Wegrzyn
Program Manager
DARPA
Day Two
Thursday May 21 2020
12:30 pm | Programmable Gene Modulation
Carlo Zambonelli
Associate Director
Beam Therapeutics
Day One
Wednesday May 20 2020
5:45 pm | Developing Assays and Tools for Base Editing
Kate Zhang
Vice President, Biological Development
Editas Medicine
Lihua Julie Zhu
Professor & Head of Bioinformatics Core
University of Massachusetts
Speaker to be Confirmed
Aldevron
Day One
Wednesday May 20 2020
3:30 pm | Slot Reserved for Aldevron
Lumeng Ye
Senior Scientist
GenScript Biotech Corp.
Day One
Wednesday May 20 2020